NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks.
In the past week, the Nordic biotech and healthcare stocks increased 0.3%, while the Danish ones specifically rose 10.6% after a stellar performance by DanCann Pharma. ViroGates also rose 48%. It was a week with capital raises as the main topic. Biosergen, Curasight, SynAct Pharma, Expres2ion, and Scandion Oncology gave both positive and negative updates on their different capital raises. Finally, FluoGuide published positive phase II results with illumination of cancer tissue in all patients of the trial.
Only 11 of the 22 Danish biotech companies had a positive share price development in the past week and 12 companies have had a positive share price performance year-to-date. Obesity continues to drive the best performances with Gubra, Zealand Pharma, and Pila Pharma having strong YTD performance. Three Danish healthcare stocks with +100% YTD return.
Danish company news
No news in the past week
No news in the past week
Biosergen has secured 100 percent of the warrants of series TO3 approximately SEK 44.9 million (Link)
Biosergen Releases Interview with Principal Investigator Dr. Pawan Singh on Drug-Resistant Fungal Infections and BSG005 (Link)
No news in the past week
CS MEDICA Welcomes the Danish Government’s Proposal to Make the Pilot Program for Prescription-Based Medicinal Cannabis Permanent (Link)
Update on the Share Distribution of CANNORDIC Shares (Link)
The exercise price for warrants of series TO2 has been set to DKK 11.50 per new share (Link)
Interim report Q3 2024 (Link)
Curasight and Curium sign global radioisotope supply agreement for uTREAT[®] (Link)
The Danish Government Proposes Permanent Scheme for Prescription-Based Medicinal Cannabis for Danish Patients (Link)
DanCann Pharma A/S Publishes Q3-2024 Report: Steady Growth in Medicinal Cannabis Prescriptions Signals Promising Future for Patients (Link)
No news in the past week
Full commitments from members of ExpreS2ion’s Board and Management holding warrants of series TO 10 (Link)
Publication of positive phase II clinical data for FG001 in patients with head and neck cancer (Link)
Genmab got new price targets. Goldman Sachs set their new price target at DKK 2,425 from DKK 2,509 and Jeffries to DKK 1,650 from DKK 2,150.
No news the past week
No news the past week
No news the past week
PILA PHARMA AB Chairman & CEO increase their holdings (Link)
PILA PHARMA ANNOUNCES INITIATION OF STUDY IN PRECLINICAL RESEARCH COLLABORATION IN CARDIOVASCULAR DISEASE (Link)
No news the past week
Warrants of series TO 2 were exercised to approximately 2.0 percent and Scandion Oncology receives approximately SEK 0.3 million (Link)
SynAct Pharma intends to carry out directed issues totalling approximately 45 MSEK and a fully guaranteed rights issue totalling approximately 20 MSEK (Link)
No news the past week
KBC initiated their coverage with a buy recommendation at DKK 980
No news the past week
No news the past week
Share price development – Danish stocks
On average, Danish biotech and healthcare stocks delivered a positive return of 10.6% following DanCann Pharma‘s stellar performance. Interestingly, the company released its Q3 report during the week, but the stock skyrocketed before it was released. Furthermore, ViroGates rose 48% without any news. Notable news includes Biosergen securing 100% of its capital raise via TO2 warrants at MSEK 44.9, Curasight setting the exercise price for its warrants of series TO2 at DKK 11.50 per new share, and Fluoguide publishing positive phase II results in head and neck cancer with 100% of the patients showing illumination of cancer tissues. Additionally, SynAct Pharma announced that they intend to carry out a direct issue of MSEK 45 and a rights issue of MSEK 20. Genmab and Zealand Pharma also got new price targets at DKK 1,650 to DKK 2,425 and DKK 980 respectively.
Gubra continues to be the best-performing stock year-to-date with a return of 415%. Pila Pharma and ViroGates have also generated more than a 100% return.
Overview of share price development the past week, year-to-date, and the last twelve month
Nordic Biotech & Healthcare Developments
In the past week, the all-Nordic index Kapital Partner Nordic Healthcare Index (KPHC) increased 0.3% to 62,01. The healthcare index performed strongly from the beginning of October last year until July and August of this year. However, since August the index has declined rapidly alongside the other indexes in the Nordics, and the 1-year return for the KPHC index has almost been erased via the past months of poor performance.
The Nordic healthcare stocks (KPHC) vs. C25, S30, and KPNGX the past year
The top three best-performing stocks in the past week
DanCann Pharma (241%) is a Danish pharmaceutical company. DanCann Pharma focuses on discovering, developing, manufacturing and commercializing novel cannabinoid medicines across a wide range of disease areas. The company manufactures and distributes prescription and over-the-counter (OTC) medicines, primarily focused on pain patients with alternative needs and management of their disease, covered by the Danish Medical Cannabis Pilot Program.
Thor Medical (147%) is a pharmaceutical company. The company specializes in the development of antibody drugs for the treatment of hematological cancer. The greatest specialization is in precision therapy used in the clinical phase. Other diseases treated include non-Hodgkins lymphoma (NHL).
BergenBio (76%) is a Norwegian oncology company currently engaged in the research and development of inhibitory drugs for the treatment of aggressive cancers. The company has developed several products whose composition aims to block the protein AXL, a protein positively related to the proliferation of cancer cells.
Resources: Refinitiv Eikon, Cision, Nordnet & company websites
